These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 34474468)
21. Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation. Zhou L; Chen W; Cao C; Shi Y; Ye W; Hu J; Wang L; Zhou W Eur J Med Chem; 2020 Mar; 189():112028. PubMed ID: 31945665 [TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and evaluation of the inhibitory selectivity of novel trans-resveratrol analogues on human recombinant CYP1A1, CYP1A2 and CYP1B1. Mikstacka R; Rimando AM; Dutkiewicz Z; Stefański T; Sobiak S Bioorg Med Chem; 2012 Sep; 20(17):5117-26. PubMed ID: 22863525 [TBL] [Abstract][Full Text] [Related]
23. Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids. Androutsopoulos VP; Papakyriakou A; Vourloumis D; Spandidos DA Bioorg Med Chem; 2011 May; 19(9):2842-9. PubMed ID: 21482471 [TBL] [Abstract][Full Text] [Related]
25. Potent inhibition of human cytochrome P450 1B1 by tetramethoxystilbene. Chun YJ; Oh YK; Kim BJ; Kim D; Kim SS; Choi HK; Kim MY Toxicol Lett; 2009 Aug; 189(1):84-9. PubMed ID: 19463925 [TBL] [Abstract][Full Text] [Related]
26. Carvedilol serves as a novel CYP1B1 inhibitor, a systematic drug repurposing approach through structure-based virtual screening and experimental verification. Wang Y; He X; Li C; Ma Y; Xue W; Hu B; Wang J; Zhang T; Zhang F Eur J Med Chem; 2020 May; 193():112235. PubMed ID: 32203789 [TBL] [Abstract][Full Text] [Related]
27. Synthesis, biological evaluation and docking studies of trans-stilbene methylthio derivatives as cytochromes P450 family 1 inhibitors. Wierzchowski M; Dutkiewicz Z; Gielara-Korzańska A; Korzański A; Teubert A; Teżyk A; Stefański T; Baer-Dubowska W; Mikstacka R Chem Biol Drug Des; 2017 Dec; 90(6):1226-1236. PubMed ID: 28632937 [TBL] [Abstract][Full Text] [Related]
28. Targeting Cytochrome P450 (CYP) 1B1 Enzyme with Four Series of A-Ring Substituted Estrane Derivatives: Design, Synthesis, Inhibitory Activity, and Selectivity. Dutour R; Roy J; Cortés-Benítez F; Maltais R; Poirier D J Med Chem; 2018 Oct; 61(20):9229-9245. PubMed ID: 30216063 [TBL] [Abstract][Full Text] [Related]
29. Predicting drug metabolism by CYP1A1, CYP1A2, and CYP1B1: insights from MetaSite, molecular docking and quantum chemical calculations. Pragyan P; Kesharwani SS; Nandekar PP; Rathod V; Sangamwar AT Mol Divers; 2014 Nov; 18(4):865-78. PubMed ID: 25028215 [TBL] [Abstract][Full Text] [Related]
30. Metformin suppresses CYP1A1 and CYP1B1 expression in breast cancer cells by down-regulating aryl hydrocarbon receptor expression. Do MT; Kim HG; Tran TT; Khanal T; Choi JH; Chung YC; Jeong TC; Jeong HG Toxicol Appl Pharmacol; 2014 Oct; 280(1):138-48. PubMed ID: 25110054 [TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of pyrrole-based chalcones as CYP1 enzyme inhibitors, for possible prevention of cancer and overcoming cisplatin resistance. Williams IS; Joshi P; Gatchie L; Sharma M; Satti NK; Vishwakarma RA; Chaudhuri B; Bharate SB Bioorg Med Chem Lett; 2017 Aug; 27(16):3683-3687. PubMed ID: 28711350 [TBL] [Abstract][Full Text] [Related]
32. CYP1B1: A Promising Target in Cancer Drug Discovery. Fabris M; Luiza Silva M; de Santiago-Silva KM; de Lima Ferreira Bispo M; Goes Camargo P Anticancer Agents Med Chem; 2023; 23(9):981-988. PubMed ID: 36655529 [TBL] [Abstract][Full Text] [Related]
33. Hydration and Structural Adaptations of the Human CYP1A1, CYP1A2, and CYP1B1 Active Sites by Molecular Dynamics Simulations. Dutkiewicz Z; Mikstacka R Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511239 [TBL] [Abstract][Full Text] [Related]
34. Inhibition of CYP1 by berberine, palmatine, and jatrorrhizine: selectivity, kinetic characterization, and molecular modeling. Lo SN; Chang YP; Tsai KC; Chang CY; Wu TS; Ueng YF Toxicol Appl Pharmacol; 2013 Nov; 272(3):671-80. PubMed ID: 23886934 [TBL] [Abstract][Full Text] [Related]
35. Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+ -ATPase inhibitors and other xenobiotics. Krusekopf S; Roots I; Hildebrandt AG; Kleeberg U Xenobiotica; 2003 Feb; 33(2):107-18. PubMed ID: 12623754 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of carcinogen-activating enzymes by 16alpha-fluoro-5-androsten-17-one. Ciolino HP; MacDonald CJ; Yeh GC Cancer Res; 2002 Jul; 62(13):3685-90. PubMed ID: 12097275 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of human recombinant cytochromes P450 CYP1A1 and CYP1B1 by trans-resveratrol methyl ethers. Mikstacka R; Przybylska D; Rimando AM; Baer-Dubowska W Mol Nutr Food Res; 2007 May; 51(5):517-24. PubMed ID: 17440990 [TBL] [Abstract][Full Text] [Related]
38. Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. Shimizu Y; Sasaki T; Yonekawa E; Yamazaki H; Ogura R; Watanabe M; Hosaka T; Shizu R; Takeshita JI; Yoshinari K J Toxicol Sci; 2021; 46(4):167-176. PubMed ID: 33814510 [TBL] [Abstract][Full Text] [Related]
39. CYP450- and COMT-derived estradiol metabolites inhibit activity of human coronary artery SMCs. Dubey RK; Gillespie DG; Zacharia LC; Barchiesi F; Imthurn B; Jackson EK Hypertension; 2003 Mar; 41(3 Pt 2):807-13. PubMed ID: 12624000 [TBL] [Abstract][Full Text] [Related]